Biomedicine & Pharmacotherapy (Feb 2024)

Recent advancements in the discovery of small-molecule non-nucleoside inhibitors targeting SARS-CoV-2 RdRp

  • Bangdi Zhou,
  • Dianming Chen,
  • Tingyan Zhang,
  • Chenggui Song,
  • Xianwu Zhang,
  • Leying Lin,
  • Jiuzhong Huang,
  • Xiaopeng Peng,
  • Yuanchang Liu,
  • Gaorong Wu,
  • Jingyuan Li,
  • Weiming Chen

Journal volume & issue
Vol. 171
p. 116180

Abstract

Read online

The RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 plays a pivotal role in the life cycle of the novel coronavirus and stands as a significant and promising target for anti-SARS-CoV-2 drugs. Non-nucleoside inhibitors (NNIs), as a category of compounds directed against SARS-CoV-2 RdRp, exhibit a unique and highly effective mechanism, effectively overcoming various factors contributing to drug resistance against nucleoside inhibitors (NIs). This review investigates various NNIs, including both natural and synthetic inhibitors, that closely interacting with the SARS-CoV-2 RdRp with valid evidences from in vitro and in silico studies.

Keywords